45 results
8-K
EX-10.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
ASSURANCE
WAIVER
SEVERABILITY
EXECUTION
ANNOUNCEMENTS AND USE OF NAMES
DISPUTE RESOLUTION AND GOVERNING LAW
CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999 … of misrepresentation or untrue statement unless and to the extent that a claim lies under this Agreement.
FURTHER ASSURANCE
Each Party hereby undertakes
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted … assurance, safety, and pharmacovigilance and related reporting.
Although Tenet plans to design the clinical trials for TNT119, Tenet anticipates
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
assurance that confidential treatment will be accorded such information.
Section 7.2. Books and Records. Seller and its Affiliates shall have
8-K
EX-99.4
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
Statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement … , whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance
8-K
EX-99.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
the grant of marketing authorizations.
However, there can be no assurance that any of the pending patent applications will issue. Furthermore, there can … be no assurance that we will benefit from any patent term extension or favorable adjustments to the term of any of the issued patents or patents
DEFM14A
9md1bi 9cds
4 Jun 24
Proxy related to merger
8:00am
PREM14A
6csfbb 31
17 May 24
Preliminary proxy related to merger
4:36pm
DEFA14A
zxurlggoj
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-2.1
bdd06qln20g
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.2
vzcvzwt291lwdljeu6g3
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
S-8
EX-5.1
7r8gpy5yc6ne9o4
28 Mar 24
Registration of securities for employees
4:27pm
8-K
5wszf11
18 Mar 24
Other Events
6:34pm